Previous Close | 36.83 |
Open | 0.00 |
Bid | 34.35 x N/A |
Ask | 0.00 x N/A |
Day's Range | 0.00 - 0.00 |
52 Week Range | |
Volume | |
Avg. Volume | 916 |
Market Cap | 2.544B |
Beta (5Y Monthly) | 0.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.01 |
Earnings Date | Aug 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company ...
LUND, SWEDEN / ACCESSWIRE / May 24, 2024 / BioInvent International (STO:BINV) TNFR2 and FcyRIIB are promising targets in immuno-oncology. BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery ...